WEST Search History

DATE: Thursday, April 17, 2003

Set Name side by side	Query	Hit Count	Set Name result set
DB=USPT,PGPB,JPAB,EPAB,DWPI; PLUR=YES; OP=ADJ			
L11	6486303	2	L11
L10	6534300	1	L10
L9	6537785	1	L9
L8	L7 and l6	15	L8
L7	moore.xa.	1540	L7
L6	furin	536	L6
L5	L4 with furin	4	L5
L4	L2 with subunit	51	L4
L3	L2 and subunit	4278	L3
L2	FUSION WITH CLEAV$	7800	L2
L1	SUBUNIT WITH FURIN	15	L1

END OF SEARCH HISTORY

```
Connecting via Winsock to STN

Welcome to STN International!  Enter x:x

LOGINID:ssspta1800exs

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE,
HCAPLUS, NTIS, ESBIOBASE, BIOTECHNO, WPIDS' AT 16:37:04 ON 17 APR 2003
FILE 'MEDLINE' ENTERED AT 16:37:04 ON 17 APR 2003
FILE 'SCISEARCH' ENTERED AT 16:37:04 ON 17 APR 2003
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)
FILE 'LIFESCI' ENTERED AT 16:37:04 ON 17 APR 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHDS' ENTERED AT 16:37:04 ON 17 APR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION
FILE 'BIOSIS' ENTERED AT 16:37:04 ON 17 APR 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)
FILE 'EMBASE' ENTERED AT 16:37:04 ON 17 APR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V.  All rights reserved.
FILE 'HCAPLUS' ENTERED AT 16:37:04 ON 17 APR 2003
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'NTIS' ENTERED AT 16:37:04 ON 17 APR 2003
All rights reserved. (2003)
FILE 'ESBIOBASE' ENTERED AT 16:37:04 ON 17 APR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.
FILE 'BIOTECHNO' ENTERED AT 16:37:04 ON 17 APR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.
FILE 'WPIDS' ENTERED AT 16:37:04 ON 17 APR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    75.54      76.38

=> s glcnac phosphotransferase
L8          101 GLCNAC PHOSPHOTRANSFERASE

=>  s l8 and (293 or hek293 or cho)
L9            7 L8 AND (293 OR HEK293 OR CHO)

=> dup rem l9
PROCESSING COMPLETED FOR L9
L10           3 DUP REM L9 (4 DUPLICATES REMOVED)

=> d 1-3

L10  ANSWER 1 OF 3  LIFESCI    COPYRIGHT 2003 CSA       DUPLICATE 1
AN   90:54469  LIFESCI
TI   Regulation of glycosylation. Three enzymes compete for a common pool of
     dolichyl phosphate in vivo.
AU   Rosenwald, A.G.; Stoll, J.; Krag, S.S.
CS   Dep. Biochem., Johns Hopkins Univ. Sch. Hyg. and Public Health, 615 N.
     Wolfe St., Baltimore, MD 21205, USA
SO   J. BIOL. CHEM., (1990) vol. 265, no. 24, pp. 14544-553.
DT   Journal
FS   L
LA   English
SL   English

L10  ANSWER 2 OF 3  LIFESCI    COPYRIGHT 2003 CSA
AN   88:24900  LIFESCI
TI   A mutant of Chinese hamster ovary cells with a reduction in levels of
```

dolichyl phosphate availabl[redacted]or glycosylation.
AU Stoll, J.; Krag, S.S.
CS Lab. Clin. Stud., Natl. Inst. Alcohol Abuse and Alcoholism, Natl. Inst. Health, Bethesda, MD 20892, USA
SO J. BIOL. CHEM., (1988) vol. 263, no. 22, pp. 10776-773.
DT Journal
FS G
LA English
SL English

L10 ANSWER 3 OF 3 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.DUPLICATE 2
AN 88181835 EMBASE
DN 1988181835
TI A mutant of Chinese hamster ovary cells with a reduction in levels of dolichyl phosphate available for glycosylation.
AU Stoll J.; Krag S.S.
CS Department of Biochemistry, Johns Hopkins University, School of Hygiene and Public Health, Baltimore, MD 21205, United States
SO Journal of Biological Chemistry, (1988) 263/22 (10766-10773).
ISSN: 0021-9258 CODEN: JBCHA3
CY United States
DT Journal
FS 029 Clinical Biochemistry
LA English
SL English

=> d 1-3 kwic

L10 ANSWER 1 OF 3 LIFESCI COPYRIGHT 2003 CSA DUPLICATE 1
AB . . . hamster ovary cells containing alterations in the levels of activity of two enzymes in the oligosaccharyl-P-P-dolichol biosynthetic pathway, namely UDP-GlcNAc:dolichyl phosphate:**GlcNAc-phosphotransferase** (GlcNAc-1-phosphotransferase) and mannosylphosphoryldolichol (Man-P-Dol) synthase. When 3E11 cells (a tunicamycin-resistant Chinese hamster ovary line containing 15 times more GlcNAc-1-phosphotransferase activity. . .
UT glycosylation; dolichyl phosphate; enzymatic activity; **CHO** cells

L10 ANSWER 2 OF 3 LIFESCI COPYRIGHT 2003 CSA
AB . . . reduced amounts. In vitro assays using membrane preparations showed that F2A8 had parental levels of glucosyl-phosphoryldolichol synthase and of UDP-GlcNAc:dolichyl phosphate:**GlcNAc-phosphotransferase** when the enzymatic determinations were done in the presence of exogenous dolichyl phosphate.
UT **CHO** cells; dolichyl phosphate; glycosylation; levels; mutants

L10 ANSWER 3 OF 3 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.DUPLICATE 2
AB . . . gel electrophoresis. In vitro assays using membrane preparations showed that F2A8 had parental levels of glucosylphosphoryldolichol synthase and of UDP-GlcNAc:dolichyl phosphate:**GlcNAc-phosphotransferase** when the enzymatic determinations were done in the presence of exogenous dolichyl phosphate. However, 5-fold less glucosylphosphoryldolichol synthase activity was. . .
CT Medical Descriptors:
*cell mutant
*protein glycosylation
cell culture
cho cell
hamster
animal cell
nonhuman
*dolichol phosphate
*mannose
radioisotope

=> dis his

(FILE 'HOME' ENTERED AT 16:[redacted]18 ON 17 APR 2003)

FILE 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS, ESBIOBASE, BIOTECHNO, WPIDS' ENTERED AT 16:14:55 ON 17 APR 2003

```
L1          206 S FURIN AND REVIEW
L2         2109 S FURIN/TI
L3            8 S L1 AND SUBUNIT
L4            5 DUP REM L3 (3 DUPLICATES REMOVED)
L5           96 S FURIN AND SUBUNIT AND FUSION
L6           82 S L5 AND CLEAV?
L7           20 DUP REM L6 (62 DUPLICATES REMOVED)
L8          101 S GLCNAC PHOSPHOTRANSFERASE
L9            7 S L8 AND (293 OR HEK293 OR CHO)
L10           3 DUP REM L9 (4 DUPLICATES REMOVED)

=> s l8 and (express? or recombina? or dna)
   6 FILES SEARCHED...
L11          21 L8 AND (EXPRESS? OR RECOMBINA? OR DNA)

=> dup rem l11
PROCESSING COMPLETED FOR L11
L12           7 DUP REM L11 (14 DUPLICATES REMOVED)

=> d 1-7

L12  ANSWER 1 OF 7  HCAPLUS  COPYRIGHT 2003 ACS        DUPLICATE 1
AN   2001:208390  HCAPLUS
DN   134:248843
TI   Use of GlcNAc-phosphotransferase and phosphodiester
     .alpha.-GlcNAcase in production of highly phosphorylated lysosomal
     hydrolases useful in treatment of lysosomal storage diseases
IN   Canfield, William M.
PA   USA
SO   PCT Int. Appl., 91 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.         KIND  DATE           APPLICATION NO.  DATE
     ---------------    ----  --------       ---------------  --------
PI   WO 2001019955      A2    20010322       WO 2000-US21970  20000914
     WO 2001019955      A3    20011004
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
             HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
             LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
             SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU,
             ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
             CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     US 6534300         B1    20030318       US 2000-635872   20000810
     US 6537785         B1    20030325       US 2000-636077   20000810
     AU 2000073303      A5    20010417       AU 2000-73303    20000914
     BR 2000014514      A     20020723       BR 2000-14514    20000914
     EP 1224266         A2    20020724       EP 2000-961335   20000914
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL
     JP 2003509043      T2    20030311       JP 2001-523727   20000914
     US 2002025550      A1    20020228       US 2001-895072   20010702
     US 2002150981      A1    20021017       US 2001-986552   20011109
PRAI US 1999-153831P    P     19990914
     US 2000-635872     A1    20000810
     WO 2000-US21970    W     20000914

L12  ANSWER 2 OF 7  BIOTECHDS COPYRIGHT 2003 THOMSON DERWENT AND ISI
AN   2001-09921  BIOTECHDS
TI   Novel N-acetylglucosamine-1-phosphotransferase and N-acetylglucosamine-1-
     phosphodiester-alpha-N-acetylglucosaminidase, useful for producing
```

phosphorylated lysosomal h[redacted]olase for treating lysosomal s[redacted]age diseases;
vector-mediated gene transfer and **expression** in host cell, monoclonal antibody and hybridoma

AU Canfield W M
PA Canfield W M
LO Oklahoma City, OK, USA.
PI WO 2001019955 22 Mar 2001
AI WO 2000-US21970 14 Sep 2000
PRAI US 1999-153831 14 Sep 1999
DT Patent
LA English
OS WPI: 2001-290356 [30]

L12 ANSWER 3 OF 7 WPIDS (C) 2003 THOMSON DERWENT
AN 2001-290925 [30] WPIDS
DNN N2001-207764 DNC C2001-089281
TI Producing a post-translationally modified heterologous polypeptide such as immunoglobulin, integrin, addressin, selectin, in plant host system, comprises altering natural post-translational modification abilities of plant.
DC B04 C06 D16 P13
IN BASSUNER, R; MANJUNATH, S; RUSSELL, D
PA (MONS) MONSANTO CO
CYC 94
PI WO 2001029242 A2 20010426 (200130)* EN 132p C12N015-82
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TZ UG ZW
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW
AU 2001015736 A 20010430 (200148) C12N015-82
EP 1224309 A2 20020724 (200256) EN C12N015-82
R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI
ADT WO 2001029242 A2 WO 2000-US29027 20001020; AU 2001015736 A AU 2001-15736 20001020; EP 1224309 A2 EP 2000-978257 20001020, WO 2000-US29027 20001020
FDT AU 2001015736 A Based on WO 200129242; EP 1224309 A2 Based on WO 200129242
PRAI US 2000-195282P 20000407; US 1999-160758P 19991021
IC ICM C12N015-82
ICS A01H005-00; C12N009-10

L12 ANSWER 4 OF 7 SCISEARCH COPYRIGHT 2003 ISI (R) DUPLICATE 2
AN 2000:206232 SCISEARCH
GA The Genuine Article (R) Number: 291QD
TI Molecular basis of variant pseudo-Hurler polydystrophy (mucolipidosis IIIC)
AU RaasRothschild A; CormierDaire V; Bao M; Genin E; Salomon R; Brewer K; Zeigler M; Mandel H; Toth S; Roe B; Munnich A; Canfield W M (Reprint)
CS UNIV OKLAHOMA, HLTH SCI CTR, STANTON L YOUNG BIOMED RES CTR 411, WK WARREN MED RES INST, OKLAHOMA CITY, OK 73104 (Reprint); UNIV OKLAHOMA, HLTH SCI CTR, STANTON L YOUNG BIOMED RES CTR 411, WK WARREN MED RES INST, OKLAHOMA CITY, OK 73104; UNIV OKLAHOMA, HLTH SCI CTR, DEPT MED, OKLAHOMA CITY, OK 73104; HADASSAH HEBREW UNIV HOSP, DEPT HUMAN GENET, IL-91120 JERUSALEM, ISRAEL; HOP NECKER ENFANTS MALAD, INSERM, U393, UNITE RECH HANDICAPS GENET ENFANT, F-75015 PARIS, FRANCE; INSERM, U155, F-75016 PARIS, FRANCE; RAMBAM MED CTR, DEPT PEDIAT, IL-35254 HAIFA, ISRAEL; UNIV OKLAHOMA, DEPT CHEM, NORMAN, OK 73019
CYA USA; ISRAEL; FRANCE
SO JOURNAL OF CLINICAL INVESTIGATION, (MAR 2000) Vol. 105, No. 5, pp. 673-681.
Publisher: AMER SOC CLINICAL INVESTIGATION INC, ROOM 4570 KRESGE I, 200 ZINA PITCHER PLACE, ANN ARBOR, MI 48109-0560.
ISSN: 0021-9738.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 35

ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L12 ANSWER 5 OF 7 MEDLINE DUPLICATE 3
AN 1998019241 MEDLINE
DN 98019241 PubMed ID: 9353330
TI UDP-GlcNAc:Ser-protein N-acetylglucosamine-1-phosphotransferase from Dictyostelium discoideum recognizes serine-containing peptides and eukaryotic cysteine proteinases.
AU Mehta D P; Etchison J R; Wu R; Freeze H H
CS The Burnham Institute, La Jolla Cancer Research Center, La Jolla, California 92037, USA.
NC RO1 32485
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1997 Nov 7) 272 (45) 28638-45.
Journal code: 2985121R. ISSN: 0021-9258.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199712
ED Entered STN: 19980109
Last Updated on STN: 20000303
Entered Medline: 19971212

L12 ANSWER 6 OF 7 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 96:911001 SCISEARCH
GA The Genuine Article (R) Number: VW686
TI Bovine UDP-N-acetylglucosamine:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase .1. Purification and subunit structure
AU Bao M; Booth J L; Elmendorf B J; Canfield W M (Reprint)
CS UNIV OKLAHOMA, HLTH SCI CTR, WK WARREN MED RES INST, BSEB 302, 941 STANTON L YOUNG BLVD, OKLAHOMA CITY, OK 73104 (Reprint); UNIV OKLAHOMA, HLTH SCI CTR, WK WARREN MED RES INST, OKLAHOMA CITY, OK 73104; UNIV OKLAHOMA, HLTH SCI CTR, DEPT MED, OKLAHOMA CITY, OK 73104
CYA USA
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (6 DEC 1996) Vol. 271, No. 49, pp. 31437-31445.
Publisher: AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC, 9650 ROCKVILLE PIKE, BETHESDA, MD 20814.
ISSN: 0021-9258.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 35
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L12 ANSWER 7 OF 7 MEDLINE DUPLICATE 4
AN 92283889 MEDLINE
DN 92283889 PubMed ID: 1317874
TI Characterization of UDP-N-acetylglucosamine:glycoprotein N-acetylglucosamine-1-phosphotransferase from Acanthamoeba castellanii.
AU Ketcham C M; Kornfeld S
CS Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110.
NC CA 08759 (NCI)
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1992 Jun 5) 267 (16) 11654-9.
Journal code: 2985121R. ISSN: 0021-9258.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199207
ED Entered STN: 19920717
Last Updated on STN: 19970203
Entered Medline: 19920706

=> d 1-7 kwic

L12 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2003 ACS DUPLICATE 1

TI Use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in production of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases

AB The lysosomal targeting pathway enzymes **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase and uses in prodn. of highly phosphorylated lysosomal hydrolases that can be used to treat lysosomal storage diseases, are disclosed. Generally, the nucleic acid mols. coding for the enzymes are incorporated into **expression** vectors that are used to transfect host cells that **express** the enzymes. The **expressed** enzymes are recovered using monoclonal antibodies capable of selectively binding to bovine **GlcNAc-phosphotransferase** and to bovine phosphodiester .alpha.-GlcNAcase. Lysosomal hydrolases having high mannose structures are treated with **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase resulting in the prodn. of asparagine-linked oligosaccharides that are highly modified with mannose 6-phosphate ("M6P"). The treated. . .

ST **GlcNAc phosphotransferase** phosphodiester alpha GlcNAcase phosphorylation lysosomal hydrolase; lysosomal storage disease enzyme replacement therapy hydrolase

IT Disease, animal
(Aspartylglucosaminuria; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Disease, animal
(Farber Lipogranulomatosis; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Disease, animal
(Fucsidosis; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Gangliosidosis
(GM1 gangliosidosis; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Mucopolysaccharidosis
(Hunter's syndrome; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Mucopolysaccharidosis
(Hurler's syndrome; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Brain, disease
(Krabbe's disease; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Mucopolysaccharidosis
(Maroteaux-Lamy syndrome; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Disease, animal
(Morquio Syndrome; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Disease, animal
(Mucolipidosis IV; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Gangliosidosis
(Sandhoff's disease; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Disease, animal
(Sanfilippo A; use of **GlcNAc-phosphotransferase** and

phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Disease, animal
(Schindler Disease; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Disease, animal
(Sialidosis; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Disease, animal
(Sly Syndrome; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Gangliosidosis
(Tay-Sachs disease; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Disease, animal
(Wolman's; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Oligosaccharides, biological studies
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(asparagine-linked, in lysosomal hydrolase; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Sialic acids
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(galactosialidosis; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Brain, disease
(metachromatic leukodystrophy; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(monoclonal; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Phosphorylation, biological
(protein; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Enzymes, biological studies
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(replacement therapy; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Glycogen storage disease
(type II; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Fabry disease
Gaucher disease
Genetic vectors
Hybridoma
Lysosomal storage disease
Lysosome
Molecular cloning
Niemann-Pick disease
Protein sequences

cDNA sequences
(use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Antibodies
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT Gangliosides
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 9012-33-3
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(A; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 9068-67-1, Sulfatase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(Deficiency, Multiple; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 9027-41-2, Hydrolase 9031-54-3, Sphingomyelinase
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(Lysosomal; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 253334-78-0P, N-Acetylglucosamine-1-phosphodiester .alpha.-N-Acetylglucosaminidase (human)
RL: BPN (Biosynthetic preparation); CAT (Catalyst use); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 3458-28-4, Mannose
RL: BOC (Biological occurrence); BSU (Biological study, unclassified); BIOL (Biological study); OCCU (Occurrence)
(in lysosomal hydrolase; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 9068-25-1, .alpha.-1,2-Mannosidase
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(inhibitor; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 528-04-1
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(transfer of N-acetyl glucosamine-1-phosphate from; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 28446-21-1, N-Acetyl glucosamine-1-phosphate
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(transfer of; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated

lysosomal hydrolases use[redacted] in treatment of lysosomal st[redacted]e diseases)

IT 331288-42-7 331288-43-8, 2: PN: WO0119955 PAGE: 53 unclaimed **DNA**
331288-44-9, 3: PN: WO0119955 PAGE: 54 unclaimed **DNA**
331288-45-0, 4: PN: WO0119955 PAGE: 54 unclaimed **DNA**
331288-46-1 331288-47-2 331288-48-3 331288-49-4 331288-50-7
331288-51-8 331288-52-9 331288-53-0 331288-54-1, 16: PN: WO0119955
PAGE: 50 unclaimed **DNA** 331288-55-2 331288-56-3
RL: PRP (Properties)
(unclaimed nucleotide sequence; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 331443-59-5 331443-60-8
RL: PRP (Properties)
(unclaimed protein sequence; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 331434-83-4 331434-84-5 331434-86-7 331434-87-8 331434-89-0
331434-90-3 331434-91-4 331434-93-6 331434-95-8 331434-97-0
331434-99-2 331435-01-9 331435-02-0
RL: PRP (Properties)
(unclaimed sequence; use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 75788-84-0P, E.C. 3.1.4.45 84012-69-1P, E.C. 2.7.8.17
RL: BPN (Biosynthetic preparation); CAT (Catalyst use); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation); USES (Uses)
(use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 7512-17-6, N-Acetylglucosamine
RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)
(use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 9001-42-7, .alpha.-Glucosidase 9001-45-0, .beta.-Glucuronidase
9001-62-1 9001-67-6, Neuraminidase 9016-17-5, Arylsulfatase
9025-35-8, .alpha.-Galactosidase A 9025-62-1, Arylsulfatase C
9027-89-8, Galactocerebrosidase 9030-36-8, Galactose 6-sulfatase
9031-11-2 9037-65-4, .alpha.-Fucosidase 9068-68-2, Arylsulfatase A
9073-56-7, .alpha.-Iduronidase 9075-63-2, .alpha.-N-Acetyl galactosaminidase 9077-06-9, Heparan N-sulfatase 37228-64-1, Glucocerebroside .beta.-Glucosidase 37288-40-7, N-Acetyl-.alpha.-glucosaminidase 37289-06-8, Acid Ceramidase 50936-59-9, Iduronate 2-sulfatase 55354-43-3, Arylsulfatase B 56467-83-5, Ceramidase 59299-00-2, N-Acetylgalactosamine-6-sulfatase 60320-99-2, N-Acetylglucosamine-6-sulfatase 79955-83-2, Acetyl CoA-.alpha.-glucosaminide N-acetyl transferase 83534-39-8, N-Glycosidase F
RL: BPR (Biological process); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 3672-15-9, Mannose 6-phosphate
RL: BSU (Biological study, unclassified); MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
(use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

IT 84444-90-6, Deoxymannojirimycin 109944-15-2, Kifunensine 149674-55-5, D-Mannoamidrazone 155501-85-2
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(use of **GlcNAc-phosphotransferase** and phosphodiester .alpha.-GlcNAcase in prodn. of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases)

L12 ANSWER 2 OF 7 BIOTECHDS COPYRIGHT 2003 THOMSON DERWENT AND ISI

TI Novel N-acetylglucosamine-1-phosphotransferase and N-acetylglucosamine-1-phosphodiester-alpha-N-acetylglucosaminidase, useful for producing phosphorylated lysosomal hydrolase for treating lysosomal storage diseases;
vector-mediated gene transfer and **expression** in host cell, monoclonal antibody and hybridoma

AB Isolated human N-acetylglucosamine-1-phosphotransferase (**GlcNAc-phosphotransferase**) and N-acetylglucosamine-1-phosphodiester-alpha-N-acetylglucosaminidase (phosphodiester-alpha-GlcNAcase, EC-3.1.4.45), is new. Also claimed are: nucleic acids encoding **GlcNAc-phosphotransferase** and phosphodiester alpha-GlcNAcase; vector containing the nucleic acids; host cell containing the vector; preparation of **GlcNAc-phosphotransferase** or phosphodiester-alpha-GlcNAcase; nucleic acids encoding mouse **GlcNAc-phosphotransferase** which has an alpha-subunit, beta-subunit and gamma-subunit and mouse phosphodiester-alpha-GlcNAcase; vector and host cell transformed with this vector; preparation of mouse **GlcNAc-phosphotransferase** and phosphodiester-alpha-GlcNAcase; lysosomal hydrolase containing a mannose-6-phosphate; phosphorylated lysosomal hydrolase; producing a high mannose lysosomal hydrolase; high mannose lysosomal hydrolase; and monoclonal antibodies produced by PT18 hybridoma (ATCC PTA 2432) or UC1 hybridoma (ATCC 2431).. The **GlcNAc-phosphotransferase** and phosphodiester-alpha-GlcNAcase are useful for producing a phosphorylated lysosomal hydrolase for treating lysosomal storage disease. (91pp)

CT HUMAN, MOUSE **RECOMBINANT** N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE, N-ACETYLGLUCOSAMINE-1-PHOSPHODIESTER-ALPHA-N-ACETYLGLUCOSAMINIDASE PREP., VECTOR-MEDIATED GENE TRANSFER, **EXPRESSION** IN HOST CELL, MONOCLONAL ANTIBODY, HYBRIDOMA, APPL. PHOSPHORYLATED LYSOSOMAL HYDROLASE PREP., LYSOSOMAL STORAGE DISEASE THERAPY ANIMAL MAMMAL ENZYME EC-3.1.4.45 **DNA** SEQUENCE PROTEIN SEQUENCE CELL CULTURE (VOL.20, NO.19)

L12 ANSWER 3 OF 7 WPIDS (C) 2003 THOMSON DERWENT

AB . . .
new.

DETAILED DESCRIPTION - Producing (M1) a post-translationally (PT) modified heterologous polypeptide in a plant host system (I) comprising:

(a) **expressing** the heterologous polypeptide, where the cells of (I) have been transformed with one or more **expression** vectors containing a nucleic acid sequence encoding a heterologous polypeptide;

(b) **expressing** a PT modifying enzyme, where the cells of (I) have been transformed with an **expression** vector containing a nucleic acid sequence encoding a PT modifying enzyme;

(c) **expressing** a heterologous polypeptide and a PT modifying enzyme where the cells of (I) have been transformed with a first **expression** vector containing a nucleic acid sequence encoding a heterologous polypeptide and a second **expression** vector containing a nucleic acid sequence encoding a PT modifying enzyme; and

(d) cross-pollinating a first (I) whose cells have been transformed with a first **expression** vector containing a nucleic acid sequence encoding a heterologous polypeptide, and a second (I), where the cells of (I) have been transformed with a second **expression** vector containing a nucleic acid sequence encoding a PT modifying enzyme.

INDEPENDENT CLAIMS are also included for the following:

(1) (I) **expressing** a PT-modified heterologous polypeptide where the natural PT modification abilities of (I) have been altered where

(a) the cells of (I) have been transformed with:

(i) an **expression** vector comprising a nucleic acid sequence encoding a heterologous polypeptide;

(ii) an **expression** vector comprising a PT modifying enzyme;

(iii) a first **expression** vector comprising a nucleic acid sequence encoding a heterologus polypeptide and a second **expression** vector comprising a nucleic acid sequence encoding a PT modifying enzyme;

(b) (I) that produces [redacted] modified heterologous polypept[redacted] and **expresses** a first **expression** vector comprising a nucleic acid sequence encoding a heterologous polypeptide and a second **express** vector comprising a nucleic acid sequence encoding a PT modifying enzyme;

(2) a plant (II) produced by M1;

(3) a seed produced from (II); and

(4) an **expression** vector comprising one or more nucleic acid sequences encoding one or more of heterologous polypeptide and a PT modifying enzyme.. . .

TECH. . .

one or more nucleic acid sequences encoding a PT modification enzyme such as glycoprotein glycosyltransferases, GlcNAc-1-phosphotransferase, GlcNAc-1-phosphodiester-N-acetylglucosaminindase, glycosidases, exoglycosidases, endoglycosidaes, **GlcNAc phosphotransferase**, protein kinases, 3'-phosphoadenosyl-5'-phosphosulfate, prolyl hydroxylase and lysyl hydroxylase. Alternately, the process of altering the natural PT-modification abilities of the (I). . . be carried out by transforming (I) comprising a nucleic acid sequence that encodes an antisense nucleic acid (antisense RNA or **DNA**) which inhibits the **expression** of at least one endogenous plant protein that comprises a plant specific-PT modification enzyme such as N-acetyl glucosaminyl transferase 1. . . cell suspension culture). Preferred Nucleic Acid: The nucleic acid sequences encoding the heterologous polypeptide are contained with one or more **expression** vectors that further comprise a signal peptide functional in the plant host system, a promoter functional in the plant host. . .

L12 ANSWER 4 OF 7 SCISEARCH COPYRIGHT 2003 ISI (R) DUPLICATE 2

AB . . . disease of lysosomal hydrolase trafficking. Unlike the related diseases, mucolipidosis II and IIIA, the enzyme affected in mucolipidosis IIIC (N-Acetylglucosamine-1-phosphotransferase [**GlcNAc-phosphotransferase**]) retains full transferase activity on synthetic substrates but lacks activity on lysosomal hydrolases. Bovine **GlcNAc-phosphotransferase** has recently been isolated as a multisubunit enzyme with the subunit structure alpha(2)beta(2)gamma(2). We cloned the cDNA for the human. . .

STP KeyWords Plus (R): UDP-N-ACETYLGLUCOSAMINE; LYSOSOMAL-ENZYME N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; I-CELL DISEASE; LINKAGE ANALYSIS; SEQUENCE; FIBROBLASTS; PHOSPHORYLATION; HETEROGENEITY; RECEPTORS; **DNA**

L12 ANSWER 5 OF 7 MEDLINE DUPLICATE 3

AB Phosphoglycosylation catalyzed by UDP-GlcNAc:Ser-protein N-acetylglucosamine-1-phosphotransferase (Ser:**GlcNAc phosphotransferase**) adds GlcNAcalpha-1-P to peptidyl-Ser of selected Dictyostelium discoideum proteins. Lysosomal cysteine proteinase (CP), proteinase-1(CP7), is the major phosphoglycosylated protein in. . . destroys the inhibitory potential of all CPs showing that transferase recognizes a conformation-dependent feature that is shared by all. Proteinase-1(CP7) **expressed** in Escherichia coli lacks GlcNAc-1-P, but it is a substrate for Ser:**GlcNAc phosphotransferase**, Km = 5.6 microM. Thus, Ser:**GlcNAc phosphotransferase** recognizes both acceptor peptide sequences and a conformational feature of eukaryotic CPs. This may be physiologically important for establishing or. . .

CT . . . Support, U.S. Gov't, P.H.S.
Chromatography, High Pressure Liquid
*Cysteine Endopeptidases: ME, metabolism
*Dictyostelium: EN, enzymology
Glycosylation
*Peptides: ME, metabolism
Phosphorylation
Recombinant Fusion Proteins: ME, metabolism
*Serine: ME, metabolism
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Substrate Specificity
*Transferases (Other Substituted Phosphate Groups):. . .

CN 0 (Peptides); 0 (**Recombinant** Fusion Proteins); EC 2.7.8

(Transferases (Other Substituted Phosphate Groups)); EC 2.7.8.17 (UDP-GlcNAc - Ser-protein N-acetylglucosamine-1-phosphotransferase); EC 3.4.22 (Cysteine Endopeptidases)

L12 ANSWER 6 OF 7 SCISEARCH COPYRIGHT 2003 ISI (R)

AB UDP-N-acetylglucosamine:lysosomal-enzyme N-acetylglucosamine-1-phosphotransferase (**GlcNAc-phosphotransferase**) catalyzes the initial step in the synthesis of the mannose 6-phosphate determinant required for efficient intracellular targeting of newly synthesized. . . green 19-agarose, and Superose 6, The partially purified enzyme was used to generate a panel of murine monoclonal antibodies, The anti-**GlcNAc-phosphotransferase** monoclonal antibody PT18 was coupled to a solid support and used to immunopurify the enzyme similar to 480,000-fold to apparent. . . a combination of analytical gel filtration chromatography, sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and amino-terminal sequencing. The data indicate that bovine **GlcNAc-phosphotransferase** is a 540,000-Da complex composed of disulfide-linked homodimers of 166,000- and 51,000-Da subunits and two identical, noncovalently associated 56,000-Da subunits.

STP KeyWords Plus (R): I-CELL DISEASE; GLYCOPROTEIN N-ACETYLGLUCOSAMINE-1-PHOSPHOTRANSFERASE; RAT-LIVER; CDNA CLONING; PROTEINS; ACETYLGLUCOSAMINYLPHOSPHOTRANSFERASE; PHOSPHODIESTERASE; PHOSPHORYLATION; **EXPRESSION**; IDENTIFICATION

L12 ANSWER 7 OF 7 MEDLINE DUPLICATE 4

AB The kinetic properties of UDP-N-acetylglucosamine:glycoprotein N-acetylglucosamine-1-phosphotransferase (**GlcNAc-phosphotransferase**) partially purified from the soil amoeba Acanthamoeba castellanii have been studied. The transferase phosphorylated the lysosomal enzymes uteroferrin and cathepsin. . . Deglycosylated RNase (RNase A) did not inhibit the phosphorylation of RNase B or uteroferrin. These results indicate that purified amoeba **GlcNAc-phosphotransferase** recognizes a protein domain present on lysosomal enzymes but absent in most nonlysosomal glycoproteins. The transferase also exhibited a marked. . . pathway for the mannose 6-phosphate recognition marker. We conclude that A. castellanii does not utilize the phosphomannosyl sorting pathway despite **expression** of very high levels of **GlcNAc-phosphotransferase**.

```
=> dis his

     (FILE 'HOME' ENTERED AT 16:12:18 ON 17 APR 2003)

     FILE 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS,
     NTIS, ESBIOBASE, BIOTECHNO, WPIDS' ENTERED AT 16:14:55 ON 17 APR 2003
L1          206 S FURIN AND REVIEW
L2         2109 S FURIN/TI
L3            8 S L1 AND SUBUNIT
L4            5 DUP REM L3 (3 DUPLICATES REMOVED)
L5           96 S FURIN AND SUBUNIT AND FUSION
L6           82 S L5 AND CLEAV?
L7           20 DUP REM L6 (62 DUPLICATES REMOVED)
L8          101 S GLCNAC PHOSPHOTRANSFERASE
L9            7 S L8 AND (293 OR HEK293 OR CHO)
L10           3 DUP REM L9 (4 DUPLICATES REMOVED)
L11          21 S L8 AND (EXPRESS? OR RECOMBINA? OR DNA)
L12           7 DUP REM L11 (14 DUPLICATES REMOVED)

=> s l8 (5a) human
   5 FILES SEARCHED...
L13          10 L8 (5A) HUMAN

=> dup rem l13
PROCESSING COMPLETED FOR L13
L14           5 DUP REM L13 (5 DUPLICATES REMOVED)
```

=> d 1-5

L14 ANSWER 1 OF 5 BIOTECHDS COPYRIGHT 2003 THOMSON DERWENT AND ISI
AN 2001-09921 BIOTECHDS
TI Novel N-acetylglucosamine-1-phosphotransferase and N-acetylglucosamine-1-phosphodiester-alpha-N-acetylglucosaminidase, useful for producing phosphorylated lysosomal hydrolase for treating lysosomal storage diseases;
vector-mediated gene transfer and expression in host cell, monoclonal antibody and hybridoma
AU Canfield W M
PA Canfield W M
LO Oklahoma City, OK, USA.
PI WO 2001019955 22 Mar 2001
AI WO 2000-US21970 14 Sep 2000
PRAI US 1999-153831 14 Sep 1999
DT Patent
LA English
OS WPI: 2001-290356 [30]

L14 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2003 ACS
AN 2001:208390 HCAPLUS
DN 134:248843
TI Use of GlcNAc-phosphotransferase and phosphodiester .alpha.-GlcNAcase in production of highly phosphorylated lysosomal hydrolases useful in treatment of lysosomal storage diseases
IN Canfield, William M.
PA USA
SO PCT Int. Appl., 91 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001019955	A2	20010322	WO 2000-US21970	20000914
	WO 2001019955	A3	20011004		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6534300	B1	20030318	US 2000-635872	20000810
	US 6537785	B1	20030325	US 2000-636077	20000810
	AU 2000073303	A5	20010417	AU 2000-73303	20000914
	BR 2000014514	A	20020723	BR 2000-14514	20000914
	EP 1224266	A2	20020724	EP 2000-961335	20000914
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
	JP 2003509043	T2	20030311	JP 2001-523727	20000914
	US 2002025550	A1	20020228	US 2001-895072	20010702
	US 2002150981	A1	20021017	US 2001-986552	20011109
PRAI	US 1999-153831P	P	19990914		
	US 2000-635872	A1	20000810		
	WO 2000-US21970	W	20000914		

L14 ANSWER 3 OF 5 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.DUPLICATE 1
AN 1991:410623 BIOSIS
DN BA92:77588
TI ELEVATED CARBOHYDRATE PHOSPHOTRANSFERASE ACTIVITY IN HUMAN HEPATOMA AND PHOSPHORYLATION OF CATHEPSIN D.
AU OHHIRA M; GASA S; MAKITA A; SEKIYA C; NAMIKI M
CS BIOCHEM. LAB., CANCER INST., HOKKAIDO UNIV. SCH. MED., KITA-KU N15 W7, SAPPORO 060, JPN.
SO BR J CANCER, (1991) 63 (6), 905-908.

CODEN: BJCAAI. ISSN: 0007-[redacted]0.
FS BA; OLD
LA English

L14 ANSWER 4 OF 5 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 91:384702 SCISEARCH
GA The Genuine Article (R) Number: FU823
TI ELEVATED CARBOHYDRATE PHOSPHOTRANSFERASE ACTIVITY IN HUMAN HEPATOMA AND PHOSPHORYLATION OF CATHEPSIN-D
AU OHHIRA M; GASA S (Reprint); MAKITA A; SEKIYA C; NAMIKI M
CS HOKKAIDO UNIV, SCH MED, INST CANC, BIOCHEM LAB, KITA KU, N15W7, SAPPORO, HOKKAIDO 060, JAPAN; ASHIKAWA MED COLL, DEPT INTERNAL MED 3, ASAHIKAWA 070, JAPAN
CYA JAPAN
SO BRITISH JOURNAL OF CANCER, (1991) Vol. 63, No. 6, pp. 905-908.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 22
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L14 ANSWER 5 OF 5 MEDLINE DUPLICATE 2
AN 87166059 MEDLINE
DN 87166059 PubMed ID: 3031074
TI Glucose-1-phosphotransferase and N-acetylglucosamine-1-phosphotransferase have distinct acceptor specificities.
AU Hiller A M; Koro L A; Marchase R B
NC EY 06714 (NEI)
GM 31381 (NIGMS)
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (1987 Mar 25) 262 (9) 4377-81.
Journal code: 2985121R. ISSN: 0021-9258.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198705
ED Entered STN: 19900303
Last Updated on STN: 20000303
Entered Medline: 19870506

=> dis his

(FILE 'HOME' ENTERED AT 16:12:18 ON 17 APR 2003)

FILE 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS, ESBIOBASE, BIOTECHNO, WPIDS' ENTERED AT 16:14:55 ON 17 APR 2003
L1 206 S FURIN AND REVIEW
L2 2109 S FURIN/TI
L3 8 S L1 AND SUBUNIT
L4 5 DUP REM L3 (3 DUPLICATES REMOVED)
L5 96 S FURIN AND SUBUNIT AND FUSION
L6 82 S L5 AND CLEAV?
L7 20 DUP REM L6 (62 DUPLICATES REMOVED)
L8 101 S GLCNAC PHOSPHOTRANSFERASE
L9 7 S L8 AND (293 OR HEK293 OR CHO)
L10 3 DUP REM L9 (4 DUPLICATES REMOVED)
L11 21 S L8 AND (EXPRESS? OR RECOMBINA? OR DNA)
L12 7 DUP REM L11 (14 DUPLICATES REMOVED)
L13 10 S L8 (5A) HUMAN
L14 5 DUP REM L13 (5 DUPLICATES REMOVED)

=> log h

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	161.07	161.91

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION

CA SUBSCRIBER PRICE -0.65 65

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 16:59:29 ON 17 APR 2003

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssspta1800exs

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Apr 08	"Ask CAS" for self-help around the clock
NEWS 3	Jun 03	New e-mail delivery for search results now available
NEWS 4	Aug 08	PHARMAMarketLetter(PHARMAML) - new on STN
NEWS 5	Aug 19	Aquatic Toxicity Information Retrieval (AQUIRE) now available on STN
NEWS 6	Aug 26	Sequence searching in REGISTRY enhanced
NEWS 7	Sep 03	JAPIO has been reloaded and enhanced
NEWS 8	Sep 16	Experimental properties added to the REGISTRY file
NEWS 9	Sep 16	CA Section Thesaurus available in CAPLUS and CA
NEWS 10	Oct 01	CASREACT Enriched with Reactions from 1907 to 1985
NEWS 11	Oct 24	BEILSTEIN adds new search fields
NEWS 12	Oct 24	Nutraceuticals International (NUTRACEUT) now available on STN
NEWS 13	Nov 18	DKILIT has been renamed APOLLIT
NEWS 14	Nov 25	More calculated properties added to REGISTRY
NEWS 15	Dec 04	CSA files on STN
NEWS 16	Dec 17	PCTFULL now covers WP/PCT Applications from 1978 to date
NEWS 17	Dec 17	TOXCENTER enhanced with additional content
NEWS 18	Dec 17	Adis Clinical Trials Insight now available on STN
NEWS 19	Jan 29	Simultaneous left and right truncation added to COMPENDEX, ENERGY, INSPEC
NEWS 20	Feb 13	CANCERLIT is no longer being updated
NEWS 21	Feb 24	METADEX enhancements
NEWS 22	Feb 24	PCTGEN now available on STN
NEWS 23	Feb 24	TEMA now available on STN
NEWS 24	Feb 26	NTIS now allows simultaneous left and right truncation
NEWS 25	Feb 26	PCTFULL now contains images
NEWS 26	Mar 04	SDI PACKAGE for monthly delivery of multifile SDI results
NEWS 27	Mar 19	APOLLIT offering free connect time in April 2003
NEWS 28	Mar 20	EVENTLINE will be removed from STN
NEWS 29	Mar 24	PATDPAFULL now available on STN
NEWS 30	Mar 24	Additional information for trade-named substances without structures available in REGISTRY
NEWS 31	Mar 24	Indexing from 1957 to 1966 added to records in CA/CAPLUS
NEWS 32	Apr 11	Display formats in DGENE enhanced
NEWS 33	Apr 14	MEDLINE Reload
NEWS 34	Apr 17	Polymer searching in REGISTRY enhanced

NEWS EXPRESS	April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP), AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or oth[redacted]similar uses is prohibited and [redacted]
result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 16:12:18 ON 17 APR 2003

=> fil .eliz
COST IN U.S. DOLLARS

	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.84	0.84

FILE 'MEDLINE' ENTERED AT 16:14:55 ON 17 APR 2003

FILE 'SCISEARCH' ENTERED AT 16:14:55 ON 17 APR 2003
COPYRIGHT (C) 2003 Institute for Scientific Information (ISI) (R)

FILE 'LIFESCI' ENTERED AT 16:14:55 ON 17 APR 2003
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'BIOTECHDS' ENTERED AT 16:14:55 ON 17 APR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOSIS' ENTERED AT 16:14:55 ON 17 APR 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'EMBASE' ENTERED AT 16:14:55 ON 17 APR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'HCAPLUS' ENTERED AT 16:14:55 ON 17 APR 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'NTIS' ENTERED AT 16:14:55 ON 17 APR 2003
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2003)

FILE 'ESBIOBASE' ENTERED AT 16:14:55 ON 17 APR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'BIOTECHNO' ENTERED AT 16:14:55 ON 17 APR 2003
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'WPIDS' ENTERED AT 16:14:55 ON 17 APR 2003
COPYRIGHT (C) 2003 THOMSON DERWENT

=> s furin and review
L1 206 FURIN AND REVIEW

=> s furin/ti
L2 2109 FURIN/TI

=> s l1 and subunit
L3 8 L1 AND SUBUNIT

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4 5 DUP REM L3 (3 DUPLICATES REMOVED)

=> d 1-5

L4 ANSWER 1 OF 5 LIFESCI COPYRIGHT 2003 CSA
AN 2001:24367 LIFESCI

TI Transgenic animal bioreact
AU Houdebine, L.M.
CS Unite de Biologie du Developpement et Biotechnologie, Institut National de la Recherche Agronomique, 78352 Jouy-en-Josas Cedex, France; E-mail: houdebine@biotec.jouy.inra.fr
SO Transgenic Research [Transgenic Res.], (20000800) vol. 9, no. 4-5, pp. 305-320. Special Issue: Frontiers in Transgenic Research..
ISSN: 0962-8819.
DT Journal
FS W2
LA English
SL English

L4 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2003 ACS
AN 2001:83194 HCAPLUS
DN 135:17605
TI Amyloidogenesis in familial British dementia is associated with a genetic defect on chromosome 13
AU Ghiso, J.; Vidal, R.; Rostagno, A.; Miravalle, L.; Holton, J. L.; Mead, S.; Revesz, T.; Plant, G.; Frangione, B.
CS Department of Pathology, New York University School of Medicine, New York, NY, 10016, USA
SO Annals of the New York Academy of Sciences (2000), 920(Molecular Basis of Dementia), 84-92
CODEN: ANYAA9; ISSN: 0077-8923
PB New York Academy of Sciences
DT Journal; General Review
LA English
RE.CNT 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:443876 HCAPLUS
DN 131:241113
TI The polymorphism of the Ebola virus glycoprotein and its potential role in pathogenesis
AU Klenk, Hans-Dieter; Volchkov, Viktor E.; Volchkova, Valentina A.; Feldmann, Heinz
CS Institut fur Virologie Philipps-Universitat Marburg, Marburg, D-35011, Germany
SO Nova Acta Leopoldina (1999), 78(307, Problems of Relevant Infectious Diseases), 141-149
CODEN: NOALA4; ISSN: 0369-5034
PB Deutsche Akademie der Naturforscher Leopoldina
DT Journal; General Review
LA German
RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
AN 1998085973 EMBASE
TI Molecular diversity in neurosecretion: Reflections on the hypothalamo-neurohypophysial system.
AU Gainer H.; Chin H.
CS H. Gainer, Laboratory of Neurochemistry, Natl. Inst. Neurol. Disorders/Stroke, Building 36, 9000 Rockville Pike, Bethesda, MD 20892, United States
SO Cellular and Molecular Neurobiology, (1998) 18/2 (211-230).
Refs: 129
ISSN: 0272-4340 CODEN: CMNEDI
CY United States
DT Journal; General Review
FS 003 Endocrinology
029 Clinical Biochemistry
LA English
SL English

L4 ANSWER 5 OF 5 MEDLINE DUPLICATE 1
AN 1998065022 MEDLINE

DN 98065022 PubMed ID: 9414
TI Three-dimensional structure of the zona pellucida.
AU Green D P
CS Department of Anatomy and Structural Biology, School of Medical Sciences, University of Otago Medical School, Dunedin, New Zealand.
SO REVIEWS OF REPRODUCTION, (1997 Sep) 2 (3) 147-56. Ref: 61
Journal code: 9602351. ISSN: 1359-6004.
CY ENGLAND: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)
General Review; (REVIEW)
(REVIEW, TUTORIAL)
LA English
FS Priority Journals
EM 199801
ED Entered STN: 19980129
Last Updated on STN: 19980129
Entered Medline: 19980115

=> dis his

(FILE 'HOME' ENTERED AT 16:12:18 ON 17 APR 2003)

FILE 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS, ESBIOBASE, BIOTECHNO, WPIDS' ENTERED AT 16:14:55 ON 17 APR 2003
L1 206 S FURIN AND REVIEW
L2 2109 S FURIN/TI
L3 8 S L1 AND SUBUNIT
L4 5 DUP REM L3 (3 DUPLICATES REMOVED)

=> s furin and subunit and fusion
L5 96 FURIN AND SUBUNIT AND FUSION

=> s l5 and cleav?
L6 82 L5 AND CLEAV?

=> dup rem l6
PROCESSING COMPLETED FOR L6
L7 20 DUP REM L6 (62 DUPLICATES REMOVED)

=> d 1-10

L7 ANSWER 1 OF 20 MEDLINE DUPLICATE 1
AN 2002430489 MEDLINE
DN 22174911 PubMed ID: 12186905
TI **Cleavage** at the **furin** consensus sequence RAR/KR(109) and presence of the intervening peptide of the respiratory syncytial virus **fusion** protein are dispensable for virus replication in cell culture.
AU Zimmer Gert; Conzelmann Karl-Klaus; Herrler Georg
CS Institut fur Virologie, Tierarztliche Hochschule Hannover, D-30559 Hannover, Germany.
SO JOURNAL OF VIROLOGY, (2002 Sep) 76 (18) 9218-24.
Journal code: 0113724. ISSN: 0022-538X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200210
ED Entered STN: 20020821
Last Updated on STN: 20021003
Entered Medline: 20021002

L7 ANSWER 2 OF 20 MEDLINE DUPLICATE 2
AN 2002199772 MEDLINE
DN 21930153 PubMed ID: 11932382
TI Amino-terminal precursor sequence modulates canine distemper virus **fusion** protein function.
AU von Messling Veronika; Cattaneo Roberto

CS Molecular Medicine Program, Mayo Clinic, Rochester, Minnesota 55905, USA.
SO JOURNAL OF VIROLOGY, (2002 May) 76 (9) 4172-80.
Journal code: 0113724. ISSN: 0022-538X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200205
ED Entered STN: 20020405
Last Updated on STN: 20020511
Entered Medline: 20020510

L7 ANSWER 3 OF 20 MEDLINE DUPLICATE 3
AN 2002131171 MEDLINE
DN 21851071 PubMed ID: 11861826
TI Enhancing the proteolytic maturation of human immunodeficiency virus type 1 envelope glycoproteins.
AU Binley James M; Sanders Rogier W; Master Aditi; Cayanan Charmagne S; Wiley Cheryl L; Schiffner Linnea; Travis Bruce; Kuhmann Shawn; Burton Dennis R; Hu Shiu-Lok; Olson William C; Moore John P
CS Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, New York 10021, USA.. jbinley@scripps.edu
NC AI45463 (NIAID)
AI47735 (NIAID)
AI49566 (NIAID)
AI49764 (NIAID)
SO JOURNAL OF VIROLOGY, (2002 Mar) 76 (6) 2606-16.
Journal code: 0113724. ISSN: 0022-538X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200203
ED Entered STN: 20020228
Last Updated on STN: 20020403
Entered Medline: 20020329

L7 ANSWER 4 OF 20 MEDLINE DUPLICATE 4
AN 2001690572 MEDLINE
DN 21602548 PubMed ID: 11739683
TI **Furin** is involved in baculovirus envelope **fusion** protein activation.
AU Westenberg Marcel; Wang Hualin; IJkel Wilfred F J; Goldbach Rob W; Vlak Just M; Zuidema Douwe
CS Laboratory of Virology, Wageningen University and Research Center, 6709 PD Wageningen, The Netherlands.
SO JOURNAL OF VIROLOGY, (2002 Jan) 76 (1) 178-84.
Journal code: 0113724. ISSN: 0022-538X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200201
ED Entered STN: 20011213
Last Updated on STN: 20020125
Entered Medline: 20020110

L7 ANSWER 5 OF 20 MEDLINE DUPLICATE 5
AN 2002003594 MEDLINE
DN 21623835 PubMed ID: 11752701
TI Multiple glycosylated forms of the respiratory syncytial virus **fusion** protein are expressed in virus-infected cells.
AU Rixon Helen W McL; Brown Craig; Brown Gaie; Sugrue Richard J
CS MRC Virology Unit, Institute of Virology, Church Street, Glasgow G11 5JR, UK.
SO JOURNAL OF GENERAL VIROLOGY, (2002 Jan) 83 (Pt 1) 61-6.
Journal code: 0077340. ISSN: 0022-1317.
CY England: United Kingdom
DT Journal; Article; (JOURNAL ARTICLE)

LA English
FS Priority Journals
EM. 200202
ED Entered STN: 20020102
Last Updated on STN: 20020220
Entered Medline: 20020219

L7 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2003 ACS DUPLICATE 6
AN 2001:636263 HCAPLUS
DN 135:176419
TI Methods for identifying candidate polynucleotide molecules encoding a protease using viral display package comprising chimeric envelope protein
IN Russell, Stephen J.; Chadwick, Mark P.; Buchholz, Christian
PA Cambridge Drug Discovery, Ltd., UK
SO PCT Int. Appl., 25 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001062972	A1	20010830	WO 2001-US5389	20010220
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	EP 1282727	A1	20030212	EP 2001-910984	20010220
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	US 2002009715	A1	20020124	US 2001-791427	20010223
	US 6387686	B2	20020514		
PRAI	US 2000-184982P	P	20000225		
	WO 2001-US5389	W	20010220		

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 7 OF 20 WPIDS (C) 2003 THOMSON DERWENT
AN 2001-582058 [65] WPIDS
DNC C2001-172577
TI Identifying polynucleotide encoding protease, comprises packaging target cell RNA into viral display packages that display chimeric or recombinant envelope proteins, and contacting with a second group of target cells.
DC B04 D16
IN CHADWICK, M P; RUSSELL, S J
PA (CAMB-N) CAMBRIDGE DRUG DISCOVERY LTD; (BIOF-N) BIOFOCUS DISCOVERY LTD; (CHAD-I) CHADWICK M P; (RUSS-I) RUSSELL S J
CYC 95

PI	WO 2001062970 A1 20010830 (200165)* EN	30p	C12Q001-68	
	RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SL SZ TR TZ UG ZW			
	W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW			
	AU 2001047206 A 20010903 (200202)		C12Q001-68	
	US 2002039729 A1 20020404 (200227)		C12Q001-68	
	EP 1266036 A1 20021218 (200301) EN		C12Q001-68	
	R: AL AT BE CH CY DE DK ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI TR			
	US 6506557 B2 20030114 (200313)		C12Q001-70	

ADT WO 2001062970 A1 WO 2001-US5381 20010220; AU 2001047206 A AU 2001-47206 20010220; US 2002039729 A1 Provisional US 2000-184981P 20000225, US 2001-792416 20010223; EP 1266036 A1 EP 2001-920120 20010220, WO 2001-US5381 20010220; US 6506557 B2 Provisional US 2000-184981P 20000225,

US 2001-792416 20010223
FDT AU 2001047206 A Based on WO 200162970; EP 1266036 A1 Based on WO 200162970
PRAI US 2000-184981P 20000225; US 2001-792416 20010223
IC ICM C12Q001-68; C12Q001-70
ICS C07H021-02; C12N005-00; C12N005-06; C12N007-00; C12N007-01; C12N015-00; C12N015-09; C12N015-63; C12N015-70; C12N015-74; C12P021-06; C12Q001-06; G01N033-53

L7 ANSWER 8 OF 20 MEDLINE DUPLICATE 7
AN 2001466733 MEDLINE
DN 21402931 PubMed ID: 11418598
TI Proteolytic activation of respiratory syncytial virus **fusion** protein. **Cleavage** at two **furin** consensus sequences.
AU Zimmer G; Budz L; Herrler G
CS Institut fur Virologie, Tierarztliche Hochschule Hannover, Bunteweg 17, D-30559 Hannover, Germany.
SO JOURNAL OF BIOLOGICAL CHEMISTRY, (2001 Aug 24) 276 (34) 31642-50. Journal code: 2985121R. ISSN: 0021-9258.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200109
ED Entered STN: 20010821
Last Updated on STN: 20030105
Entered Medline: 20010920

L7 ANSWER 9 OF 20 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 2001:372489 SCISEARCH
GA The Genuine Article (R) Number: 427CF
TI Purification and characterization of a Ca2+-independent endoprotease activity from peripheral blood lymphocytes: Involvement in HIV-1 gp160 maturation
AU Bendjennat M; Bahbouhi B; Bahraoui E (Reprint)
CS Univ Toulouse 3, Lab Immunovirol, EA 3038, UFR SVT, F-31062 Toulouse, France (Reprint)
CYA France
SO BIOCHEMISTRY, (17 APR 2001) Vol. 40, No. 15, pp. 4800-4810. Publisher: AMER CHEMICAL SOC, 1155 16TH ST, NW, WASHINGTON, DC 20036 USA. ISSN: 0006-2960.
DT Article; Journal
LA English
REC Reference Count: 48
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L7 ANSWER 10 OF 20 MEDLINE DUPLICATE 8
AN 2000111319 MEDLINE
DN 20111319 PubMed ID: 10644371
TI Proteolytic **cleavage** of the **fusion** protein but not membrane **fusion** is required for measles virus-induced immunosuppression in vitro.
AU Weidmann A; Maisner A; Garten W; Seufert M; ter Meulen V; Schneider-Schaulies S
CS Institute for Virology and Immunobiology, University of W]urzburg, D-97078 W]urzburg, Germany.
SO JOURNAL OF VIROLOGY, (2000 Feb) 74 (4) 1985-93. Journal code: 0113724. ISSN: 0022-538X.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200003
ED Entered STN: 20000314
Last Updated on STN: 20000314
Entered Medline: 20000302

=> d 11-20

L7 ANSWER 11 OF 20 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 2000:766157 SCISEARCH
GA The Genuine Article (R) Number: 360ZM
TI The **cleavage** activation and sites of glycosylation in the **fusion** protein of Hendra virus
AU Michalski W P (Reprint); Crameri G; Wang L F; Shiell B J; Eaton B
CS CSIRO ANIM HLTH, AUSTRALIAN ANIM HLTH LAB, PRIVATE BAG 24, GEELONG, VIC 3220, AUSTRALIA (Reprint)
CYA AUSTRALIA
SO VIRUS RESEARCH, (25 SEP 2000) Vol. 69, No. 2, pp. 83-93.
Publisher: ELSEVIER SCIENCE BV, PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS.
ISSN: 0168-1702.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 46
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L7 ANSWER 12 OF 20 MEDLINE DUPLICATE 9
AN 2000431780 MEDLINE
DN 20390113 PubMed ID: 10930660
TI **Cleavage** of the respiratory syncytial virus **fusion** protein is required for its surface expression: role of **furin**.
AU Bolt G; Pedersen L O; Birkeslund H H
CS Department of Medical Microbiology and Immunology, Panum Institute, University of Copenhagen, Blegdamsvej 3, 2200 N, Copenhagen, Denmark.. gb@kvl.dk
SO VIRUS RESEARCH, (2000 Jun) 68 (1) 25-33.
Journal code: 8410979. ISSN: 0168-1702.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 200009
ED Entered STN: 20000922
Last Updated on STN: 20000922
Entered Medline: 20000914

L7 ANSWER 13 OF 20 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 2000:213418 SCISEARCH
GA The Genuine Article (R) Number: 292MA
TI Proteolytic processing of Marburg virus glycoprotein
AU Volchkov V E (Reprint); Volchkova V A; Stroher U; Becker S; Dolnik O; Cieplik M; Garten W; Klenk H D; Feldmann H
CS UNIV MARBURG, INST VIROL, ROBERT KOCH STR 17, D-35037 MARBURG, GERMANY (Reprint)
CYA GERMANY
SO VIROLOGY, (1 MAR 2000) Vol. 268, No. 1, pp. 1-6.
Publisher: ACADEMIC PRESS INC, 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495.
ISSN: 0042-6822.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 46
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L7 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:795994 HCAPLUS
DN 132:31744
TI Gene probes used for genetic profiling in healthcare screening and planning
IN Roberts, Gareth Wyn
PA Genostic Pharma Ltd., UK
SO PCT Int. Appl., 745 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9964627	A2	19991216	WO 1999-GB1780	19990604

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

PRAI	GB 1998-12099	A	19980606
	GB 1998-13291	A	19980620
	GB 1998-13611	A	19980624
	GB 1998-13835	A	19980627
	GB 1998-14110	A	19980701
	GB 1998-14580	A	19980707
	GB 1998-15438	A	19980716
	GB 1998-15574	A	19980718
	GB 1998-15576	A	19980718
	GB 1998-16085	A	19980724
	GB 1998-16086	A	19980724
	GB 1998-16921	A	19980805
	GB 1998-17097	A	19980807
	GB 1998-17200	A	19980808
	GB 1998-17632	A	19980814
	GB 1998-17943	A	19980819

L7 ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:795993 HCAPLUS
DN 132:31743
TI Gene probes used for genetic profiling in healthcare screening and planning
IN Roberts, Gareth Wyn
PA Genostic Pharma Limited, UK
SO PCT Int. Appl., 149 pp.
CODEN: PIXXD2
DT Patent
LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9964626	A2	19991216	WO 1999-GB1779	19990604

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

	CA 2330929	AA	19991216	CA 1999-2330929	19990604
	AU 9941586	A1	19991230	AU 1999-41586	19990604
	AU 9941587	A1	19991230	AU 1999-41587	19990604
	GB 2339200	A1	20000119	GB 1999-12914	19990604
	GB 2339200	B2	20010912		
	EP 1084273	A1	20010321	EP 1999-925207	19990604

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

PRAI	GB 1998-12098	A	19980606
	GB 1998-28289	A	19981223
	GB 1998-16086	A	19980724
	GB 1998-16921	A	19980805
	GB 1998-17097	A	19980807
	GB 1998-17200	A	19980808
	GB 1998-17632	A	19980814

GB 1998-17943 A 1998[redacted]9
WO 1999-GB1779 W 19990604

L7 ANSWER 16 OF 20 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:753357 HCAPLUS
DN 132:9591
TI Polyproteins **cleavable** by ubiquitous endoproteases to release several constituent therapeutic proteins and expression constructs for use in gene therapy
IN Gaken, Johannes Adrianus; Farzaneh, Farzin; Russell, Stephen James
PA UK
SO PCT Int. Appl., 44 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9960135	A1	19991125	WO 1999-GB1609	19990521
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2333144	AA	19991125	CA 1999-2333144	19990521
	AU 9940508	A1	19991206	AU 1999-40508	19990521
	AU 753785	B2	20021031		
	EP 1080206	A1	20010307	EP 1999-923745	19990521
	EP 1080206	B1	20030402		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
	JP 2002515251	T2	20020528	JP 2000-549741	19990521
PRAI	GB 1998-10999	A	19980521		
	WO 1999-GB1609	W	19990521		

OS MARPAT 132:9591
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 17 OF 20 HCAPLUS COPYRIGHT 2003 ACS
AN 1999:673041 HCAPLUS
DN 131:282025
TI Improved methods for making hormone heterodimers for therapeutic and disagnostic purposes
IN Moyle, William R.
PA University of Medicine & Dentistry of New Jersey, USA
SO PCT Int. Appl., 73 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9953065	A1	19991021	WO 1999-US8018	19990413
	W: AU, CA, JP				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	US 6486303	B1	20021126	US 1998-59625	19980414
	AU 9935561	A1	19991101	AU 1999-35561	19990413
PRAI	US 1998-59625	A	19980414		
	WO 1999-US8018	W	19990413		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 18 OF 20 MEDLINE
AN 1999185011 MEDLINE

DN 99185011 PubMed ID: 10085
TI Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells.
AU Singh Y; Klimpel K R; Goel S; Swain P K; Leppla S H
CS Centre for Biochemical Technology, Delhi 110007, India.
SO INFECTION AND IMMUNITY, (1999 Apr) 67 (4) 1853-9.
Journal code: 0246127. ISSN: 0019-9567.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199904
ED Entered STN: 19990511
Last Updated on STN: 19990511
Entered Medline: 19990426

L7 ANSWER 19 OF 20 SCISEARCH COPYRIGHT 2003 ISI (R)
AN 1999:617619 SCISEARCH
GA The Genuine Article (R) Number: 223DP
TI The glycoproteins of Marburg and Ebola virus and their potential roles in pathogenesis
AU Feldmann H; Volchkov V E; Volchkova V A; Klenk H D (Reprint)
CS UNIV MARBURG, INST VIROL, POSTFACH 2360, D-35011 MARBURG, GERMANY (Reprint); UNIV MARBURG, INST VIROL, D-35011 MARBURG, GERMANY
CYA GERMANY
SO ARCHIVES OF VIROLOGY, (AUG 1999) Supp. [15], pp. 159-169.
Publisher: SPRINGER-VERLAG WIEN, SACHSENPLATZ 4-6, PO BOX 89, A-1201 VIENNA, AUSTRIA.
ISSN: 0304-8608.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 53
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L7 ANSWER 20 OF 20 MEDLINE DUPLICATE 10
AN 1999097444 MEDLINE
DN 99097444 PubMed ID: 9878618
TI The role of subtilisin-like proprotein convertases for **cleavage** of the measles virus **fusion** glycoprotein in different cell types.
AU Bolt G; Pedersen I R
CS Panum Institute, University of Copenhagen, Blegdamsvej 3, Copenhagen N, 2200, Denmark.. G.Bolt@immi.ku.dk
SO VIROLOGY, (1998 Dec 20) 252 (2) 387-98.
Journal code: 0110674. ISSN: 0042-6822.
CY United States
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199901
ED Entered STN: 19990209
Last Updated on STN: 20000303
Entered Medline: 19990128

=> dis his

(FILE 'HOME' ENTERED AT 16:12:18 ON 17 APR 2003)

FILE 'MEDLINE, SCISEARCH, LIFESCI, BIOTECHDS, BIOSIS, EMBASE, HCAPLUS, NTIS, ESBIOBASE, BIOTECHNO, WPIDS' ENTERED AT 16:14:55 ON 17 APR 2003
L1 206 S FURIN AND REVIEW
L2 2109 S FURIN/TI
L3 8 S L1 AND SUBUNIT
L4 5 DUP REM L3 (3 DUPLICATES REMOVED)
L5 96 S FURIN AND SUBUNIT AND FUSION
L6 82 S L5 AND CLEAV?
L7 20 DUP REM L6 (62 DUPLICATES REMOVED)

```
=> log h
```